Current pharmacotherapies and immunotherapy in cocaine addiction;Pharmacothérapies actuelles et immunothérapie dans l'addiction à la cocaïne

Presse Medicale

Volumn 37, Issue 4 PART 2, 2008, Pages 689-698

  Karila, Laurent ^a,b,c   Weinstein, Aviv ^d   Benyamina, Amine ^a,b,e   Coscas, Sarah ^a,b,e   Leroy, Claire ^c   Noble, Florence ^f   Lowenstein, William ^g   Aubin, Henri Jean ^a,b,e   Lépine, Jean Pierre ^f,h   Reynaud, Michel ^a,b,e  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c DIF   (France)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e Universite Paris Sud   (France)

^f CNRS   (France)

^g Clinique Montevideo   (France)

^h HÔPITAL FERNAND WIDAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ARIPIPRAZOLE; BACLOFEN; DISULFIRAM; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; MODAFINIL; OLANZAPINE; PLACEBO; RISPERIDONE; TIAGABINE; TOPIRAMATE; VIGABATRIN;

CLINICAL TRIAL; COCAINE DEPENDENCE; DRUG EXPOSURE; DRUG MECHANISM; DRUG SCREENING; HUMAN; IMMUNOTHERAPY; NEUROBIOLOGY; NEUROIMAGING; POPULATION; SHORT SURVEY; SYMPTOMATOLOGY;

EID: 41249101094     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2007.08.015     Document Type: Short Survey

References (106)

1. Karila L., Coscas S., Benyamina A., Edel Y., Lépine J., Lowenstein W., et al. L'addiction à la cocaine : données actuelles. Rev Prat Med Gen 21 (2007) 790-793
2. Fowler J.S., Volkow N.D., Wang G.J., Gatley S.J., and Logan J. [(11)]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl Med Biol 28 5 (2001) 561-572
3. Gatley S.J., Volkow N.D., Gifford A.N., Fowler J.S., Dewey S.L., Ding Y.S., et al. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacology (Berl) 146 1 (1999) 93-100
4. Volkow N.D., Ding Y.S., Fowler J.S., and Wang G.J. Cocaine addiction: hypothesis derived from imaging studies with PET. J Addict Dis 15 4 (1996) 55-71
5. Volkow N.D., Fowler J.S., and Wang G.J. Positron emission tomography and single-photon emission computed tomography in substance abuse research. Semin Nucl Med 33 2 (2003) 114-128
6. Koob G.F., and Weiss F. Neuropharmacology of cocaine and ethanol dependence. Recent Dev Alcohol 10 (1992) 201-233
7. Lingford-Hughes A., and Nutt D. Neurobiology of addiction and implications for treatment. Br J Psychiatry 182 (2003) 97-100
8. Laviolette S.R., and van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat Rev Neurosci 5 1 (2004) 55-65
9. Kalivas P.W., and Volkow N.D. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 162 8 (2005) 1403-1413
10. Smith G.S., Schloesser R., Brodie J.D., Dewey S.L., Logan J., Vitkun S.A., et al. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology 18 1 (1998) 18-25
11. Kalivas P.W. Glutamate systems in cocaine addiction. Curr Opin Pharmacol 4 1 (2004) 23-29
12. Kalivas P.W., McFarland K., Bowers S., Szumlinski K., Xi Z.X., and Baker D. Glutamate transmission and addiction to cocaine. Ann N Y Acad Sci 1003 (2003) 169-175
13. Koob G.F. Neurobiology of addiction. Toward the development of new therapies. Ann N Y Acad Sci 909 (2000) 170-185
14. Goldstein R.Z., and Volkow N.D. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 159 10 (2002) 1642-1652
15. Leiderman D.B., Shoptaw S., Montgomery A., Bloch D.A., Elkashef A., LoCastro J., et al. Cocaine Rapid Efficacy Screening Trial (Crest): a paradigm for the controlled evaluation of candidate medications for cocaine dependence. Addiction 100 Suppl 1 (2005) 1-11
16. Vocci F., and Ling W. Medications development: successes and challenges. Pharmacol Ther 108 1 (2005) 94-108
17. Dackis C., and O'Brien C. Glutamatergic agents for cocaine dependence. Ann N Y Acad Sci 1003 (2003) 328-345
18. Dackis C.A. Recent advances in the pharmacotherapy of cocaine dependence. Curr Psychiatry Rep 6 5 (2004) 323-331
19. Karila L., Gorelick D., Weinstein A., Noble F., Benyamina A., Coscas S., et al. New treatments for cocaine dependence - a focused review. Int J Neuropsychopharmacol 10 (2007) 1-14
20. Ballon J.S., and Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 67 4 (2006) 554-566
21. Duteil J., Rambert F.A., Pessonnier J., Hermant J.F., Gombert R., and Assous E. Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals. Eur J Pharmacol 180 1 (1990) 49-58
22. Ferraro L., Antonelli T., O'Connor W.T., Tanganelli S., Rambert F., and Fuxe K. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport 8 13 (1997) 2883-2887
23. Mignot E., Nishino S., Guilleminault C., and Dement W.C. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 17 5 (1994) 436-437
24. Madras B., Xie Z., Lin Z., Jassen A., Panas H., Lynch L., et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther (2006)
25. Ferraro L., Antonelli T., O'Connor W.T., Tanganelli S., Rambert F.A., and Fuxe K. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci Lett 253 2 (1998) 135-138
26. de Saint Hilaire Z., Orosco M., Rouch C., Blanc G., and Nicolaidis S. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport 12 16 (2001) 3533-3537
27. Wisor J.P., Nishino S., Sora I., Uhl G.H., Mignot E., and Edgar D.M. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 21 5 (2001) 1787-1794
28. Boutrel B., and Koob G.F. What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep 27 6 (2004) 1181-1194
29. Wisor J.P., and Eriksson K.S. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience 132 4 (2005) 1027-1034
30. Nishino S., and Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 52 1 (1997) 27-78
31. Dackis C.A., Lynch K.G., Yu E., Samaha F.F., Kampman K.M., Cornish J.W., et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 70 1 (2003) 29-37
32. Kaufman M.J., Levin J.M., Kukes T.J., Villafuerte R.A., Hennen J., Lukas S.E., et al. Illicit cocaine use patterns in intravenous-naive cocaine users following investigational intravenous cocaine administration. Drug Alcohol Depend 58 1-2 (2000) 35-42
33. Wong Y.N., King S.P., Laughton W.B., McCormick G.C., and Grebow P.E. Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers. J Clin Pharmacol 38 3 (1998) 276-282
34. Wong Y.N., Simcoe D., Hartman L.N., Laughton W.B., King S.P., McCormick G.C., et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 39 1 (1999) 30-40
35. Wong Y.N., Wang L., Hartman L., Simcoe D., Chen Y., Laughton W., et al. Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers. J Clin Pharmacol 38 10 (1998) 971-978
36. Donovan J.L., DeVane C.L., Malcolm R.J., Mojsiak J., Chiang C.N., Elkashef A., et al. Modafinil influences the pharmacokinetics of intravenous cocaine in healthy cocaine-dependent volunteers. Clin Pharmacokinet 44 7 (2005) 753-765
37. Simon P., Hemet C., and Costentin J. Analysis of stimulant locomotor effects of modafinil in various strains of mice and rats. Fundam Clin Pharmacol 10 5 (1996) 431-435
38. Nicolaidis S., and De Saint Hilaire Z. Nonamphetamine awakening agent modafinil induces feeding changes in the rat. Brain Res Bull 32 2 (1993) 87-90
39. Kampman K.M., Alterman A.I., Volpicelli J.R., Maany I., Muller E.S., Luce D.D., et al. Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment. Psychol Addict Behav 15 1 (2001) 52-59
40. Dackis C.A., Kampman K.M., Lynch K.G., Pettinati H.M., and O'Brien C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30 1 (2005) 205-211
41. Deroche-Gamonet V., Darnaudery M., Bruins-Slot L., Piat F., Le Moal M., and Piazza P.V. Study of the addictive potential of modafinil in naive and cocaine-experienced rats. Psychopharmacology (Berl) 161 4 (2002) 387-395
42. Myrick H., Malcolm R., Taylor B., and LaRowe S. Modafinil: preclinical, clinical, and post-marketing surveillance - a review of abuse liability issues. Ann Clin Psychiatry 16 2 (2004) 101-109
43. Muller U., Steffenhagen N., Regenthal R., and Bublak P. Effects of modafinil on working memory processes in humans. Psychopharmacology (Berl) 177 1-2 (2004) 161-169
44. Turner D.C., Robbins T.W., Clark L., Aron A.R., Dowson J., and Sahakian B.J. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 165 3 (2003) 260-269
45. Turner D.C., Clark L., Dowson J., Robbins T.W., and Sahakian B.J. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry 55 10 (2004) 1031-1040
46. Turner D.C., Clark L., Pomarol-Clotet E., McKenna P., Robbins T.W., and Sahakian B.J. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29 7 (2004) 1363-1373
47. Cousins M.S., Roberts D.C., and de Wit H. GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend 65 3 (2002) 209-220
48. Gorelick D.A., Gardner E.L., and Xi Z.X. Agents in development for the management of cocaine abuse. Drugs 64 14 (2004) 1547-1573
49. Kalivas P.W., Churchill L., and Klitenick M.A. GABA and enkephalin projection from the nucleus accumbens and ventral pallidum to the ventral tegmental area. Neuroscience 57 4 (1993) 1047-1060
50. Febo M., and Segarra A.C. Cocaine alters GABA(B)-mediated G-protein activation in the ventral tegmental area of female rats: modulation by estrogen. Synapse 54 1 (2004) 30-36
51. Sofuoglu M., and Kosten T.R. Novel approaches to the treatment of cocaine addiction. CNS Drugs 19 1 (2005) 13-25
52. Kushner S.A., and Unterwald E.M. Chronic cocaine administration decreases the functional coupling of GABA(B) receptors in the rat ventral tegmental area as measured by baclofen-stimulated 35S-GTPgammaS binding. Life Sci 69 9 (2001) 1093-1102
53. Roberts D.C. Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction. Physiol Behav 86 1-2 (2005) 18-20
54. Roberts D.C., Andrews M.M., and Vickers G.J. Baclofen attenuates the reinforcing effects of cocaine in rats. Neuropsychopharmacology 15 4 (1996) 417-423
55. Roberts D.C., and Brebner K. GABA modulation of cocaine self-administration. Ann N Y Acad Sci 909 (2000) 145-158
56. Di Ciano P., and Everitt B.J. The GABA(B) receptor agonist baclofen attenuates cocaine- and heroin-seeking behavior by rats. Neuropsychopharmacology 28 3 (2003) 510-518
57. Fadda P., Scherma M., Fresu A., Collu M., and Fratta W. Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse 50 1 (2003) 1-6
58. Ling W., Shoptaw S., and Majewska D. Baclofen as a cocaine anti-craving medication: a preliminary clinical study. Neuropsychopharmacology 18 5 (1998) 403-404
59. Brebner K., Childress A.R., and Roberts D.C. A potential role for GABA(B) agonists in the treatment of psychostimulant addiction. Alcohol Alcohol 37 5 (2002) 478-484
60. Shoptaw S., Yang X., Rotheram-Fuller E.J., Hsieh Y.C., Kintaudi P.C., Charuvastra V.C., et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry 64 12 (2003) 1440-1448
61. Breslow M.F., Fankhauser M.P., Potter R.L., Meredith K.E., Misiaszek J., and Hope Jr. D.G. Role of gamma-aminobutyric acid in antipanic drug efficacy. Am J Psychiatry 146 3 (1989) 353-356
62. Drake R.G., Davis L.L., Cates M.E., Jewell M.E., Ambrose S.M., and Lowe J.S. Baclofen treatment for chronic posttraumatic stress disorder. Ann Pharmacother 37 9 (2003) 1177-1181
63. Krupitsky E.M., Burakov A.M., Ivanov V.B., Krandashova G.F., Lapin I.P., Grinenko A., et al. Baclofen administration for the treatment of affective disorders in alcoholic patients. Drug Alcohol Depend 33 2 (1993) 157-163
64. Vocci F.J., and Elkashef A. Pharmacotherapy and other treatments for cocaine abuse and dependence. Curr Opin Psychiatry 18 3 (2005) 265-270
65. Johnson B.A. Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs 19 10 (2005) 873-896
66. Ait Daoud N, Johnson B. Open-label trial of topiramate for treating cocaine dependence. Presented at the College on Problem of Drug Dependence annual meeting. In. San Juan; 2004, Jun 13.
67. Kampman K.M., Pettinati H., Lynch K.G., Dackis C., Sparkman T., Weigley C., et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 75 3 (2004) 233-240
68. Kushner S.A., Dewey S.L., and Kornetsky C. The irreversible gamma-aminobutyric acid (GABA) transaminase inhibitor gamma-vinyl-GABA blocks cocaine self-administration in rats. J Pharmacol Exp Ther 290 2 (1999) 797-802
69. Gerasimov M.R., Schiffer W.K., Gardner E.L., Marsteller D.A., Lennon I.C., Taylor S.J., et al. GABAergic blockade of cocaine-associated cue-induced increases in nucleus accumbens dopamine. Eur J Pharmacol 414 2-3 (2001) 205-209
70. Brodie J.D., Figueroa E., Laska E.M., and Dewey S.L. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 55 2 (2005) 122-125
71. Sofuoglu M., and Kosten T.R. Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opin Emerg Drugs 11 1 (2006) 91-98
72. Berger S.P., Winhusen T.M., Somoza E.C., Harrer J.M., Mezinskis J.P., Leiderman D.B., et al. A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction 100 Suppl 1 (2005) 58-67
73. Gonzalez G., Sevarino K., Sofuoglu M., Poling J., Oliveto A., Gonsai K., et al. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction 98 11 (2003) 1625-1632
74. Gonzalez G., Desai R., Sofuoglu M., Poling J., Oliveto A., Gonsai K., et al. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend (2006)
75. Bisaga A., Aharonovich E., Garawi F., Levin F.R., Rubin E., Raby W.N., et al. A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend 81 3 (2006) 267-274
76. Hart C.L., Haney M., Collins E.D., Rubin E., and Foltin R.W. Smoked cocaine self-administration by humans is not reduced by large gabapentin maintenance doses. Drug Alcohol Depend 86 2-3 (2007) 274-277
77. Suh J.J., Pettinati H.M., Kampman K.M., and O'Brien C.P. The status of disulfiram: a half of a century later. J Clin Psychopharmacol 26 3 (2006) 290-302
78. O'Shea B. Disulfiram revisited. Hosp Med 61 12 (2000) 849-851
79. Gossop M., and Carroll K.M. Disulfiram, cocaine, and alcohol: two outcomes for the price of one?. Alcohol Alcohol 41 2 (2006) 119-120
80. Higgins S.T., Budney A.J., Bickel W.K., Hughes J.R., and Foerg F. Disulfiram therapy in patients abusing cocaine and alcohol. Am J Psychiatry 150 4 (1993) 675-676
81. Carroll K.M., Nich C., Ball S.A., McCance E., and Rounsavile B.J. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 93 5 (1998) 713-727
82. Carroll K.M., Nich C., Ball S.A., McCance E., Frankforter T.L., and Rounsaville B.J. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction 95 9 (2000) 1335-1349
83. Carroll K.M., Fenton L.R., Ball S.A., Nich C., Frankforter T.L., Shi J., et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 61 3 (2004) 264-272
84. Kosten T.R., and Biegel D. Therapeutic vaccines for substance dependence. Expert Rev Vaccines 1 3 (2002) 363-371
85. Berger S.P., Hall S., Mickalian J.D., Reid M.S., Crawford C.A., Delucchi K., et al. Haloperidol antagonism of cue-elicited cocaine craving. Lancet 347 9000 (1996) 504-508
86. Newton T.F., Ling W., Kalechstein A.D., Uslaner J., and Tervo K. Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Res 102 3 (2001) 227-233
87. De La Garza II R., Newton T.F., and Kalechstein A.D. Risperidone diminishes cocaine-induced craving. Psychopharmacology (Berl) 178 2-3 (2005) 347-350
88. Smelson D.A., Losonczy M.F., Davis C.W., Kaune M., Williams J., and Ziedonis D. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry 47 7 (2002) 671-675
89. Smelson D.A., Roy A., and Roy M. Risperidone diminishes cue-elicited craving in withdrawn cocaine-dependent patients. Can J Psychiatry 42 9 (1997) 984
90. Grabowski J., Rhoades H., Silverman P., Schmitz J.M., Stotts A., Creson D., et al. Risperidone for the treatment of cocaine dependence: randomized, double-blind trial. J Clin Psychopharmacol 20 3 (2000) 305-310
91. Kampman K.M., Pettinati H., Lynch K.G., Sparkman T., and O'Brien C.P. A pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend 70 3 (2003) 265-273
92. Marra D., Warot D., Berlin I., Hispard E., Notides C., Tilikete S., et al. Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial. Alcohol Clin Exp Res 26 10 (2002) 1545-1552
93. Vocci F.J., Acri J., and Elkashef A. Medication development for addictive disorders: the state of the science. Am J Psychiatry 162 8 (2005) 1432-1440
94. El-Sayeh H.G., Morganti C., and Adams C.E. Aripiprazole for schizophrenia: systematic review. Br J Psychiatry 189 (2006) 102-108
95. Feltenstein M.W., Altar C.A., and See R.E. Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biol Psychiatry (2006)
96. Beresford T.P., Clapp L., Martin B., Wiberg J.L., Alfers J., and Beresford H.F. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol 25 4 (2005) 363-366
97. Baker D.A., McFarland K., Lake R.W., Shen H., Toda S., and Kalivas P.W. N-acetyl cysteine-induced blockade of cocaine-induced reinstatement. Ann N Y Acad Sci 1003 (2003) 349-351
98. Mardikian P.N., Larowe S.D., Hedden S., Kalivas P.W., and Malcolm R.J. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: A pilot study. Prog Neuropsychopharmacol Biol Psychiatry (2006)
99. Baker D.A., McFarland K., Lake R.W., Shen H., Tang X.C., Toda S., et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci 6 7 (2003) 743-749
100. LaRowe S.D., Mardikian P., Malcolm R., Myrick H., Kalivas P., McFarland K., et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict 15 1 (2006) 105-110
101. Fox B.S., Kantak K.M., Edwards M.A., Black K.M., Bollinger B.K., Botka A.J., et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 2 10 (1996) 1129-1132
102. Heading CE. TA-CD. Xenova. IDrugs 2002, 5(11):1070-1074.
103. Fox B.S. Development of a therapeutic vaccine for the treatment of cocaine addiction. Drug Alcohol Depend 48 3 (1997) 153-158
104. Kantak K.M. Anti-cocaine vaccines: antibody protection against relapse. Expert Opin Pharmacother 4 2 (2003) 213-218
105. Kosten T.R., Rosen M., Bond J., Settles M., Roberts J.S., Shields J., et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 20 7-8 (2002) 1196-1204
106. Martell B.A., Mitchell E., Poling J., Gonsai K., and Kosten T.R. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 58 2 (2005) 158-164